Amycretin (zenagamtide)
Also known as: zenagamtide
Browse our Amycretin (zenagamtide) articles and comparisons. Start with the drug explainer for the mechanism and trial evidence, or choose a comparison below.
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Novo Nordisk |
| Mechanism | Unimolecular GLP-1 + amylin dual agonist |
| Administration | Once-daily oral tablet OR once-weekly subcutaneous injection |
| Peak weight loss | ~22% subq at 36 weeks / ~13.1% oral at 12 weeks (Phase 1) |
| Status | Phase 3 for obesity initiated Q1 2026 |
Drug explainer
What Is Amycretin (Zenagamtide)? Oral and Injectable Trial Data →Novo Nordisk’s investigational GLP-1/amylin medicine has oral and injectable trials; the AMAZE Phase 3 program is underway.
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.